No Data
No Data
Express News | Castle Biosciences Inc : Leerink Partners Cuts Target Price to $35 From $40
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle Biosciences Honored With a Top Workplaces USA Award for Fourth Consecutive Year
Castle Biosciences Announces Publication of Papers on DecisionDx-Melanoma Test
Castle Biosciences Announced The Recent Publication Of Two Papers In The World Journal Of Surgical Oncology And Cancer Medicine Sharing Reports From The Prospective, Multicenter Decide Study Demonstrating The Significant Impact Of The Company's...